Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer

详细信息    查看全文

• 作者：Konstantina Skaltsa ; Cristina Ivanescu ; Shevani Naidoo ; De Phung…
• 刊名：Targeted Oncology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：12
• 期：1
• 页码：111-121
• 全文大小：621KB
• 刊物主题：Oncology; Biomedicine, general;
• 出版者：Springer International Publishing
• ISSN：1776-260X
• 卷排序：12

文摘

BackgroundIf patients in oncology trials receive subsequent therapy, standard intention-to-treat (ITT) analyses may inaccurately estimate the overall survival (OS) effect of the investigational product. In this context, a post-hoc analysis of the phase 3 PREVAIL study was performed with the aim to compare enzalutamide with placebo in terms of OS, adjusting for potential confounding from switching to antineoplastic therapies that are not part of standard metastatic castration-resistant prostate cancer (mCRPC) treatment pathways in some jurisdictions.